NDAINTRAVENOUSINJECTABLE
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
AVOPEF (etoposide) by Viatris (2) is topoisomerase inhibitors [moa]. Approved for diffuse large b-cell lymphoma, small cell lung cancer, germ cell tumor and 3 more indications. First approved in 2026.
Drug data last refreshed 19h ago
Mechanism of Action
Topoisomerase Inhibitors
Pharmacologic Class:
Topoisomerase Inhibitor
Indications (6)
Worked on AVOPEF at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.